Oppenheimer Maintains Outperform on RxSight, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman has maintained an Outperform rating on RxSight (NASDAQ:RXST) and increased the price target from $38 to $46, indicating a positive outlook on the company's stock.
January 08, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst reaffirms Outperform rating on RxSight and raises price target to $46, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst like Steven Lichtman typically signals a bullish outlook on the stock, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100